Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 1/2009

01-01-2009 | original article

Multiagent Chemotherapy for Isolated Colorectal Liver Metastases: A Single-centered Retrospective Study

Authors: Srinevas K. Reddy, Gloria Broadwater, Donna Niedzwiecki, Andrew S. Barbas, Herbert I. Hurwitz, Johanna C. Bendell, Michael A. Morse, Bryan M. Clary

Published in: Journal of Gastrointestinal Surgery | Issue 1/2009

Login to get access

Abstract

Background

Few studies identifying variables associated with prognosis after resection of colorectal liver metastases (CLM) account for treatment with multiagent chemotherapy (fluoropyrmidines with irinotecan, oxaliplatin, bevacizumab, and/or cetuximab). The objective of this retrospective study was to determine the effect of multiagent chemotherapy on long-term survival after resection of CLM.

Methods

Demographics, clinicopathologic tumor characteristics, treatments, and long-term outcomes were reviewed.

Results

From 1996 to 2006, 230 patients underwent resection of CLM. Treatment strategies before and after resection included fluoropyrimidine monotherapy (n = 34 and n = 39), multiagent chemotherapy (n = 81 and n = 73), and observation (n = 115 and n = 118). Prehepatectomy treatment strategy was not associated with overall survival. Actuarial 4-year survival was 63%, 39%, and 40% for patients treated with multiagent chemotherapy, fluoropyrimidine monotherapy, and observation after hepatectomy, p = 0.06. Posthepatectomy multiagent chemotherapy (p = 0.04, HR 0.52 [0.27–1.03]), duration of posthepatectomy chemotherapy treatment of 2 months or longer (p = 0.05, HR 0.49 [0.25–0.99]), carcino-embryonic antigen level >10 ng/mL (p = 0.03, HR 2.09, 95% CI [1.32–3.32]), and node positive primary tumor (p = 0.002, HR 1.79 [1.06–3.02]) were associated with overall survival in multivariate analysis.

Conclusions

The association of posthepatectomy multiagent chemotherapy with overall survival in this retrospective study indicates the need for prospective randomized trials comparing multiagent chemotherapy and fluoropyrimidine monotherapy for CLM.
Literature
1.
go back to reference Niu R, Yan TD, Zhu JC, et al. Recurrence and survival after hepatic resection with or without cryotherapy for liver metastases from colorectal carcinoma. Ann Surg Oncol. 2007;14:2078–2087.PubMedCrossRef Niu R, Yan TD, Zhu JC, et al. Recurrence and survival after hepatic resection with or without cryotherapy for liver metastases from colorectal carcinoma. Ann Surg Oncol. 2007;14:2078–2087.PubMedCrossRef
4.
go back to reference Kato T, Yasui K, Hirai T, et al. Therapeutic results for hepatic metastases of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 2003;46:S22–S31.PubMed Kato T, Yasui K, Hirai T, et al. Therapeutic results for hepatic metastases of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 2003;46:S22–S31.PubMed
6.
go back to reference Figueras J, Torras J, Valls C, et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum. 2007;50:478–488. doi:10.1007/s10350-006-0817-6.PubMedCrossRef Figueras J, Torras J, Valls C, et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum. 2007;50:478–488. doi:10.​1007/​s10350-006-0817-6.PubMedCrossRef
14.
23.
go back to reference Laurent C, Cunha AS, Couderc P, et al. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg. 2003;90:1131–1136. doi:10.1002/bjs.4202.PubMedCrossRef Laurent C, Cunha AS, Couderc P, et al. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg. 2003;90:1131–1136. doi:10.​1002/​bjs.​4202.PubMedCrossRef
26.
go back to reference Jamison RL, Donohue JH, Nagorney DM, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg. 1997;132:505–511.PubMed Jamison RL, Donohue JH, Nagorney DM, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg. 1997;132:505–511.PubMed
28.
go back to reference Hughes K, Scheele J, Sugarbaker PH. Surgery for colorectal cancer metastatic to the liver: optimizing the results of treatment. Surg Clin North Am. 1989;69:339–359.PubMed Hughes K, Scheele J, Sugarbaker PH. Surgery for colorectal cancer metastatic to the liver: optimizing the results of treatment. Surg Clin North Am. 1989;69:339–359.PubMed
29.
go back to reference Hughes KS, Rosenstein RB, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of long-term survivors. Dis Colon Rectum. 1988;31:1–4. doi:10.1007/BF02552560.PubMedCrossRef Hughes KS, Rosenstein RB, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of long-term survivors. Dis Colon Rectum. 1988;31:1–4. doi:10.​1007/​BF02552560.PubMedCrossRef
31.
go back to reference Bradley AL, Chapman WC, Wright JK, et al. Surgical experience with hepatic colorectal metastasis. Am Surg. 1999;65:560–566.PubMed Bradley AL, Chapman WC, Wright JK, et al. Surgical experience with hepatic colorectal metastasis. Am Surg. 1999;65:560–566.PubMed
32.
go back to reference Jenkins LT, Millikan KW, Bines SD, et al. Hepatic resection for metastatic colorectal cancer. Am Surg. 1997;63:605–610.PubMed Jenkins LT, Millikan KW, Bines SD, et al. Hepatic resection for metastatic colorectal cancer. Am Surg. 1997;63:605–610.PubMed
33.
34.
go back to reference Nagashima I, Takada T, Matsuda K, et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobiliary Pancreat Surg. 2004;11:79–83. doi:10.1007/s00534-003-0851-x.PubMedCrossRef Nagashima I, Takada T, Matsuda K, et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobiliary Pancreat Surg. 2004;11:79–83. doi:10.​1007/​s00534-003-0851-x.PubMedCrossRef
35.
go back to reference Nicoli N, Casaril A, Mangiante G, et al. Surgical treatment for liver metastases from colorectal carcinoma: results of 228 patients. Hepatogastroenterology. 2004;51:1810–1814.PubMed Nicoli N, Casaril A, Mangiante G, et al. Surgical treatment for liver metastases from colorectal carcinoma: results of 228 patients. Hepatogastroenterology. 2004;51:1810–1814.PubMed
36.
go back to reference Hohenberger P, Schlag PM, Gerneth T, et al. Pre- and postoperative carcinoembryonic antigen determinations in hepatic resection for colorectal metastases: predictive value and implications for adjuvant treatment based on multivariate analysis. Ann Surg. 1994;219:135–143. doi:10.1097/00000658-199402000-00005.PubMedCrossRef Hohenberger P, Schlag PM, Gerneth T, et al. Pre- and postoperative carcinoembryonic antigen determinations in hepatic resection for colorectal metastases: predictive value and implications for adjuvant treatment based on multivariate analysis. Ann Surg. 1994;219:135–143. doi:10.​1097/​00000658-199402000-00005.PubMedCrossRef
37.
go back to reference Seifert JK, Bottger TC, Weigel TF, et al. Prognostic factors following liver resection for hepatic metastases from colorectal cancer. Hepatogastroenterology. 2000;47:239–246.PubMed Seifert JK, Bottger TC, Weigel TF, et al. Prognostic factors following liver resection for hepatic metastases from colorectal cancer. Hepatogastroenterology. 2000;47:239–246.PubMed
38.
go back to reference Harms J, Obst T, Thorban S, et al. The role of surgery in the treatment of liver metastases for colorectal cancer patients. Hepatogastroenterology. 1999;46:2321–2328.PubMed Harms J, Obst T, Thorban S, et al. The role of surgery in the treatment of liver metastases for colorectal cancer patients. Hepatogastroenterology. 1999;46:2321–2328.PubMed
43.
go back to reference de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial including survival, with a median follow-up of six years. J Clin Oncol. 2007;25:165s. (ASCO Annual Meeting Proceedings Part 1. 25:Abstr 2007, 2007). de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial including survival, with a median follow-up of six years. J Clin Oncol. 2007;25:165s. (ASCO Annual Meeting Proceedings Part 1. 25:Abstr 2007, 2007).
44.
go back to reference Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NASBP C-07. J Clin Oncol. 2007;25:2198–2204. doi:10.1200/JCO.2006.08.2974.PubMedCrossRef Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NASBP C-07. J Clin Oncol. 2007;25:2198–2204. doi:10.​1200/​JCO.​2006.​08.​2974.PubMedCrossRef
46.
go back to reference Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24:4976–4982. doi:10.1200/JCO.2006.06.8353.PubMedCrossRef Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24:4976–4982. doi:10.​1200/​JCO.​2006.​06.​8353.PubMedCrossRef
47.
go back to reference Nordlinger B, Sorbye H, Coulette L, et al. Final results of the EORTC intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol 2007;25:2s. (ASCO Annual Meeting Proceedings Part I. 25:Abstr LBA5, 2007). Nordlinger B, Sorbye H, Coulette L, et al. Final results of the EORTC intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol 2007;25:2s. (ASCO Annual Meeting Proceedings Part I. 25:Abstr LBA5, 2007).
48.
go back to reference Strasberg SM. Terminology of liver anatomy and liver resections: coming to grips with hepatic Babel. J Am Coll Surg. 1997;184:413–434.PubMed Strasberg SM. Terminology of liver anatomy and liver resections: coming to grips with hepatic Babel. J Am Coll Surg. 1997;184:413–434.PubMed
Metadata
Title
Multiagent Chemotherapy for Isolated Colorectal Liver Metastases: A Single-centered Retrospective Study
Authors
Srinevas K. Reddy
Gloria Broadwater
Donna Niedzwiecki
Andrew S. Barbas
Herbert I. Hurwitz
Johanna C. Bendell
Michael A. Morse
Bryan M. Clary
Publication date
01-01-2009
Publisher
Springer-Verlag
Published in
Journal of Gastrointestinal Surgery / Issue 1/2009
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-008-0617-5

Other articles of this Issue 1/2009

Journal of Gastrointestinal Surgery 1/2009 Go to the issue